AI assistant
X4 Pharmaceuticals, Inc — Director's Dealing 2017
Nov 15, 2017
34355_dirs_2017-11-15_88461eec-6a0f-494b-9278-f91ab1278aae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15
Reporting Person: Gerngross Tillman U. (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 102549 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $1.85 | 2023-04-18 | Common Stock (26809) | Direct | |
| Stock Option (right to buy) | $9.39 | 2026-07-19 | Common Stock (38675) | Direct | |
| Series D Convertible Preferred Stock | $ | Common Stock (90272) | Direct |
Footnotes
F1: This option fully vested on September 1, 2014.
F2: This option was granted on July 20, 2016, and vests over four years, with 25% of the original 38,675 shares underlying the option having vested on July 20, 2017 and 2.0833% of the original 38,675 shares vesting monthly thereafter, subject to continued service.
F3: The Series D Convertible Preferred Stock is convertible into Common Stock on a 0.29300-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.